TNG fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. Its products include TG4001, TG4050, TG6002, BT-001 & TG6050. The company was founded in December 1979 and is headquartered in Strasbourg, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
TNG does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company